Skip to main content
. 2016 Oct 1;6(10):2140–2161.

Figure 9.

Figure 9

A merged network based on the top five upstream regulators lipopolysaccharide, nuclear NFkB (complex) and the cytokines TNF, IL1A, and CSF2. IL1A is also included in the differentially expressed probe set list. Increased activation is predicted by a z-score > 2 (Table 3). The network is based on the list of 429 differentially expressed probe sets that intersect between the four comparison groups (Figure 5B), and reflecting the expression values derived from the two comparison groups, brain metastatic PTC vs. non-brain metastatic PTCs and brain metastatic PTC (TR) vs. non-brain metastatic PTCs (Supplement Table 1). Upregulated molecules include ADORA1, ADORA3, ANGPTL4, APOD, AQP5, AQP9, B3GNT5, BAG3, BCL2A1, BCL3, BIRC3, BLZF1, CCL13, CCL18, CCL2, CCL20, CCL22, CD209, CD83, CISH, CSF2RA, CX3CL1, CXCL1, CXCL14, CXCL2, CXCL8, DMBT1, EFNA1, ELF3, FPR2, G0S2, GFAP, HCAR2, HCAR3, HMOX1, HP, HSPA1A/HSPA1B, HSPA8, ICAM1, IER3, IGK, IGKC, IL17C, IL1A, IL1B, IL1R2, IL2RA, IL32, IL6, IL7R, ITGB6, KIF20A, KRT17, LAD1, LDHA, LRG1, LYN, MFI2, MMP7, MTTP, NAMPT, NEDD9, NUP62, ORM1, OSM, PDZK1IP1, PI3, PIM1, PLAGL2, PLAUR, PMAIP1, PPARG, PTGS2, QSOX1, REL, RFX5, RHOH, RRAD, RRM2, S100A8, S100A9, SAA1, SAA2, SFTPA1, SFTPB, SLC2A1, SOD2, STEAP4, TFAP2A, TLR1, TNFAIP2, TNFRSF9, TREM1, and ZC3H12A. Downregulated molecules include SCARB1, SLC30A4, TRIB1, TRPC1, UACA, and VEGFC. The pathway was overlaid with the Molecule Activity Predictor to precalculate further molecular effects, as outlined in the prediction legend.